Related Experiment Video
Updated: Sep 28, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Inhibition of lung adenocarcinoma LA795 in mice by recombinant human endostatin
De-Ling Liu1, Jin-Xu Wen, Wan-Cheng Tong
1Department of Respiratory Disease, Fuzhou General Hospital, Fuzhou 350025, China.
Abstract:
OBJECTIVE: To evaluate the inhibitory effect of recombinant human endostatin on tumor growth and metastasis of adenocarcinoma LA795 in mice. METHODS: Recombinant human endostatin was purified rom endostadin-expressing pCX clones. LA795 cells were inoculated subcutaneously on the back of T739 mice, which were randomized into 2 groups. From the tenth day on, treatment group was given 20 mg/kg recombinant human endostatin subcutaneously daily for 14 consecutive days, and the control group received PBS in the same manner. The sizes of the subcutaneous tumors, lung weights, the number of metastases over the lung surface and the survival time of the mice were observed. RESULTS: The tumor sizes of the treatment group in creased slowly from (650+/-201) mm3 to (1 642+/-21) mm3 when compared with those of the control group which showed and increase from (623+/-248) mm3 to (9 194+/-952) mm3. The lung weight of the 2 groups was (190+/-25) mg and (324+/-43) mg respectively, and the number of lung sung surface metastases was 8+/-2 and 22+/-8 for each. The average survival time of the rats in the 2 groups was 48 d and 27 d, respectively. All parameters measured between the 2 groups showed significant differences (P<0.01). CONCLUSION: Recom binent human endostatin has strong inhibitory effect on both the growth of primary tumor and metastasis of lung adenocarcinoma LA795 cells, and prolongs the survival time of the tumor-bearing mice.
Insights
Recombinant human endostatin significantly inhibited lung adenocarcinoma LA795 tumor growth and metastasis in mice. This treatment also extended the survival time of tumor-bearing mice.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lung adenocarcinoma is a significant cause of cancer mortality.
- Endostatin is a potent endogenous angiogenesis inhibitor.
- Targeting tumor angiogenesis is a promising therapeutic strategy.
Purpose of the Study:
- To investigate the efficacy of recombinant human endostatin in inhibiting tumor growth and metastasis.
- To evaluate the impact of endostatin on the survival of mice bearing lung adenocarcinoma.
Main Methods:
- Purification of recombinant human endostatin from endostatin-expressing pCX clones.
- Subcutaneous inoculation of LA795 lung adenocarcinoma cells in T739 mice.
- Administration of recombinant human endostatin (20 mg/kg daily) or PBS to randomized groups for 14 days.
Main Results:
- Significantly reduced tumor size in the endostatin treatment group compared to controls (1642 mm3 vs 9194 mm3).
- Markedly decreased lung weight and number of lung surface metastases in treated mice (8+/-2 vs 22+/-8).
- Prolonged average survival time in the endostatin group (48 days vs 27 days).
Conclusions:
- Recombinant human endostatin demonstrates potent anti-tumor and anti-metastatic effects.
- Endostatin therapy significantly improves survival in a murine model of lung adenocarcinoma.
- These findings support endostatin as a potential therapeutic agent for lung cancer.